Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction
Status:
Completed
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This proof-of-concept, open-label non-randomized clinical trial was conducted at a tertiary
care cardiac center in Karachi, Pakistan. Patients with HFrEF were prescribed
Sacubitril/Valsartan and followed for 12 weeks for the assessment of safety and tolerability.
Safety measures included incidence of hypotension, renal dysfunction, hyperkalemia, and
angioedema
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Cardiovascular Diseases, Karachi